Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AtriCure Inc Issues FY 2013 Guidance; EBITDA Guidance Below Analysts' Estimates


Thursday, 28 Feb 2013 04:04pm EST 

AtriCure Inc announced that for fiscal 2013, it expects revenue to be in the range of $76.5 - $78.0 million and adjusted EBITDA, a non-GAAP measure, to be a loss in the range of $3.0 to $5.0 million, including the impact of the Medical Device Tax which is estimated to be in the range of $0.8 - $1.0 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $77.8 million and EBITDA of $(2.8) million for fiscal 2013. 

Company Quote

15.89
-0.08 -0.50%
23 Jul 2014